Evotec SE announced on November 16, 2026 that it has been awarded a $2.9 million grant from the Gates Foundation to extend its human stem cell-based fetal developmental safety screening program for a further three years.
Key Highlights
- Grant amount: $2.9 million awarded by the Gates Foundation to Evotec SE.
- Three-year extension: The funding extends a project originally initiated in 2023 for an additional three years.
- Prior screening volume: Over 5,000 compounds were screened across nine grantee programs during the initial three-year collaboration, according to the filing.
- Technology basis: The platform combines human induced pluripotent stem cell (hiPSC) models with industrial-scale screening capabilities to identify compounds that may pose developmental risks.
- Platform scope: Evotec disclosed that it leverages more than 25 hiPSC-derived cellular models as part of its broader New Approach Methodologies portfolio.
- Global health focus: The grant supports researchers working on global health programs in assessing potential fetal development risks earlier in drug discovery.
Gates Foundation Extends Evotec's Developmental Safety Screening Collaboration
According to the announcement, Evotec SE (NASDAQ:EVO) (Frankfurt Prime Standard: EVT) has received a new $2.9 million grant from the Gates Foundation. The funding is intended to continue support for Evotec's human stem cell-based New Approach Methodologies (NAMs) platform, which the company describes as designed to identify potential safety risks to fetal development in novel drug candidates. The filing states that this new grant extends a project first initiated in 2023 by a further three years.
The filing reports that during the initial three-year period of the collaboration, more than 5,000 compounds were screened across nine grantee programs. Evotec disclosed that the development and validation of the platform are described in a recent bioRxiv preprint. The company's Chief Scientific Officer, Dr. Joanna Holbrook, stated in the announcement: "Identifying potential safety risks early in the drug development process is essential to the efficient advancement of better medicines for global health priorities." She added that the platform "allows researchers to investigate potential effects on prenatal development based on the behavior of human cells, helping them make better-informed decisions about which drug candidates to pursue."
Evotec described its broader NAMs portfolio as combining machine learning with high-throughput experimentation, high-content imaging, and interpretable genome-scale molecular data to predict toxicology across organs. The filing also noted that these technologies "aim to improve translational relevance" and can "potentially reduce reliance on animal testing." The company disclosed that it operates a global team of around 4,500 experts from sites in Europe and the United States. The announcement contains forward-looking statements which, according to the company's own cautionary language, involve known and unknown risks and are subject to significant uncertainties beyond Evotec's control.
What Was Disclosed
Evotec SE disclosed receipt of a $2.9 million Gates Foundation grant extending a 2023 collaboration for three additional years, focused on using its hiPSC-based platform to screen drug candidates for potential fetal developmental safety risks in support of global health research programs.




Please wait processing your request...